Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Also known as: Blastic Plasmacytoid Dendritic Cell Neoplasm

DrugDrug NameDrug Description
DB14731TagraxofuspTagraxofusp is an IL-3 conjugated truncated diphtheria toxin.[L4895] It is composed by the catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3.[L4897, L4898] Tagraxofusp was developed by Stemline Therapeutics Inc and FDA approved on December 21, 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm.[L4894] This drug achieved approval after being designed with the title of breakthrough therapy, priority review, and orphan drug status.[L4893] Tagraxofusp has been designed as an orphan drug in EU since November 2015.[L4898]
DrugDrug NamePhaseStatusCount
DB00493Cefotaxime1Recruiting1
DB00531Cyclophosphamide1Recruiting1
DB01073Fludarabine1Recruiting2
DB11581Venetoclax1Recruiting1
DB14731Tagraxofusp1 / 2Active Not Recruiting1
DB14731Tagraxofusp1 / 2Completed1
DB01008Busulfan2Not Yet Recruiting1
DB00493Cefotaxime2Recruiting1
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01073Fludarabine2Not Yet Recruiting1
DB01073Fludarabine2Recruiting1
DB00563Methotrexate2Not Yet Recruiting1
DB00563Methotrexate2Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB06132Nivolumab2Recruiting1
DB09035Nivolumab2Recruiting1
DB00864Tacrolimus2Not Yet Recruiting1
DB00864Tacrolimus2Recruiting1
DB04572Thiotepa2Not Yet Recruiting1
DB04572Thiotepa2Recruiting1
DB00091CiclosporinNot AvailableActive Not Recruiting1
DB01073FludarabineNot AvailableActive Not Recruiting1
DB00688Mycophenolate mofetilNot AvailableActive Not Recruiting1